We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Abbott, Genentech and WEHI Collaborate to Research and Develop New Anti-Cancer Drugs
News

Abbott, Genentech and WEHI Collaborate to Research and Develop New Anti-Cancer Drugs

Abbott, Genentech and WEHI Collaborate to Research and Develop New Anti-Cancer Drugs
News

Abbott, Genentech and WEHI Collaborate to Research and Develop New Anti-Cancer Drugs

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Abbott, Genentech and WEHI Collaborate to Research and Develop New Anti-Cancer Drugs"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

The Walter and Eliza Hall Institute of Medical Research (WEHI) announced that Abbott, Genentech and WEHI have joined in a tripartite research collaboration to discover new anti-cancer drugs.

"This exciting three party research collaboration among world leaders in this field may increase the chance of translating basic scientific research in apoptosis, the process of programmed cell death, as carried out by our collaborators over recent years, into novel targeted cancer therapeutics," says Dr. Julian Clark, Head of Business Development at WEHI.

"We are excited to collaborate with Abbott and Genentech based on their expertise in apoptosis and strong track records in the development of small molecule drugs. We believe both will be excellent collaborators in bringing forward potential novel cancer therapeutics that target the apoptosis pathway," explains WEHI cancer researcher, Dr. David Huang.

Under the terms of the collaboration the three parties are engaged in a drug discovery research program, with Genentech and Abbott being responsible for the development, manufacturing and commercialization of potential new drugs. The discovery stage of the collaboration involves an integrated approach engaging research sites in South San Francisco, the Chicago area and Melbourne. Financial terms of the collaboration will not be disclosed.

WEHI's director, Professor Suzanne Cory, emphasizes that "WEHI's first priority is to work to ensure that cancer patients benefit from the results of our fundamental research and all three parties in the collaboration are committed to the discovery and development of improved cancer treatments that enable patients to live longer and healthier lives."

Advertisement